On March 12, 2014, Recro Pharma, Inc (NASDAQ:REPH) completed its initial public offering (“IPO”). In relation to such IPO, the Company filed information reflected in a slide presentation as a free writing prospectus on February 13, 2014. Recro Pharma Inc (NASDAQ:REPH) stock performance was -4.64% in last session and finished the day at $6.98. Traded volume was 43.6K shares in the last session and the average volume of the stock remained 129.19K shares. Recro Pharma Inc (NASDAQ:REPH) insider ownership is 45.70%.

Ruthigen Inc (NASDAQ:RTGN)’s IPO provides strong investment opportunity based on relative valuations and addressing unmet market need with potential multi-billion dollar market. Tetraphase Pharmaceuticals in turn presents a short opportunity as a potentially inferior comp a year ahead of Ruthigen Inc (NASDAQ:RTGN) with >10x the market cap. Ruthigen Inc (NASDAQ:RTGN) dropped -1.32 percent to $6.75 Tuesday on volume of 80.8K shares. The intra-day range of the stock was $6.51 to $6.85. Ruthigen Inc (NASDAQ:RTGN) has a market capitalization of $28.35million.

MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management,  announced the closing of its initial public offering of 5,750,000 ordinary shares at a price to the public of $14.00 per share. Mediwound Ltd (NASDAQ:MDWD)’s stock on Apr 01, 2014 reported a decrease of -1.94% to the closing price of $14.13. Its fifty two weeks range is $13.75 -$19.31. The total market capitalization recorded $288.24million. The overall volume in the last trading session was 265.5K shares. In its share capital, MDWD has 20.35million outstanding shares.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) saw an uptick in trading volume on Friday after the company announced better than expected quarterly earnings, American Banking & Market Newsreports. 357,389 shares were traded during mid-day trading, an increase of 103% from the previous session’s volume of 176,045 shares. On Tuesday, shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) dropped -6.16% to close the day at $26.51. Company return on investment (ROI) is 16.60% and its monthly performance is recorded as -29.40%.